Biomea Fusion EASD data: BMF-219 increases beta cell mass in human islets, improves glycemic control in rat T2D models

Biomea Fusion, Inc.

BMF-219 increased beta cell mass in ex vivo human donor islets, first such translational data presented.
In ZDF rats, OGTT AUC reduced 54% vs vehicle (p<0.001) during treatment; 40% reduction maintained 2 weeks after washout (p<0.05).
In STZ rats, BMF-219 nearly doubled HOMA-B (+96%) and restored non-fasting glucose to near-normal by day 8.
BMF-219 reduced blood lipemic levels and body weight in both ZDF and STZ rat models.
Company remains on track to file IND for BMF-219 in type 2 diabetes in second half of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.